Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | VP of Finance | February 15, 2019 | February 19, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Karyopharm Therapeutics Inc.
Report date February 15, 2019 · Filed February 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.21 · Expires 2029-02-14 | Direct | 17,000 |
Reported balance
After 2019-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-15 · Grant · Acquired 17,000 · Balance 17,000 F1: This option was granted on February 15, 2019. The shares underlying this option vest as to 25% of the shares on February 15, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 8,500 |
Reported balance
After 2019-02-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-15 · Grant · Acquired 8,500 · Balance 8,500 F2: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F3: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on February 15, 2019. The shares underlying this option vest as to 25% of the shares on February 15, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F2: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock.
F3: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2019 Filed Feb 19, 2019 16:32 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantRestricted Stock Units · Derivative | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011095 · doc4.xml · derivative · entry 2 Peters Cameron · CIK 0001765269 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 16:32 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $9.21 | $0.00 |
DisclosureSEC source: 0001209191-19-011095 · doc4.xml · derivative · entry 1 Peters Cameron · CIK 0001765269 · VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2029-02-14 F1 · derivative.exercise_date: This option was granted on February 15, 2019. The shares underlying this option vest as to 25% of the shares on February 15, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.